Universitat de Lleida
    • English
    • català
    • español
  • català 
    • English
    • català
    • español
  • Inicia la sessió
Repositori Obert UdL
Visualitza l'element 
  •   Inici
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • Visualitza l'element
  •   Inici
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • Visualitza l'element
JavaScript is disabled for your browser. Some features of this site may not work without it.

Chronic treatment with the AMPA agonist AICAR prevents skeletal muscle pathology but fails to improve clinical outcome in a mouse model of severe spinal muscular atrophy

Thumbnail
Visualitza/Obre
023438.pdf (2.721Mb)
Sol·licita una còpia
Data de publicació
2016
Autor/a
Cerveró Cebrià, Clàudia
Montull, Neus
Tarabal Mostazo, Olga
Piedrafita Llorens, Lídia
Esquerda Colell, Josep
Calderó i Pardo, Jordi
Citació recomanada
Cerveró Cebrià, Clàudia; Montull, Neus; Tarabal Mostazo, Olga; Piedrafita Llorens, Lídia; Esquerda Colell, Josep; Calderó i Pardo, Jordi; . (2016) . Chronic treatment with the AMPA agonist AICAR prevents skeletal muscle pathology but fails to improve clinical outcome in a mouse model of severe spinal muscular atrophy. Neurotherapeutics, 2016, vol. 13, p. 198-216. https://doi.org/10.1007/s13311-015-0399-x.
Impacte


Logo de Web of Science    citacions a Web of Science

Logo d'Scopus    citacions a Scopus

Logo de Google Acadèmic  Google Acadèmic
Compartir
Exportar a Mendeley
Metadades
Mostra el registre d'unitat complet
Resum
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by spinal and brainstem motor neuron (MN) loss and skeletal muscle paralysis. Currently there is no effective treatment other than supportive care to ameliorate the quality of life of SMA patients. Some studies have reported that physical exercise is potentially beneficial in SMA by improving muscle strength and motor function. The AMP-activated protein kinase (AMPK) agonist 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) has been reported to be an exercise mimetic agent that is able to regulate muscle metabolism and increase endurance both at rest and during exercise. Chronic AICAR administration has been shown to ameliorate the dystrophic muscle phenotype and motor behavior in the mdx mouse, a model of Duchenne muscular dystrophy. Here, we investigated whether chronic AICAR treatment was able to elicit beneficial effects on motor abilities and neuromuscular histopathology in a mouse model of severe SMA (the SMNΔ7 mouse). We report that AICAR improved skeletal muscle atrophy and structural changes found in neuromuscular junctions of SMNΔ7 animals. However, although AICAR prevented the loss of glutamatergic excitatory synapses on MNs, this compound was not able to mitigate MN loss or the microglial and astroglial reaction occurring in the spinal cord of diseased mice. Moreover, no improvement in both survival and motor performance was seen in SMNΔ7 animals treated with AICAR. The beneficial effects of AICAR in SMA found in our study are SMN-independent, since no changes in the expression of this protein were seen in the spinal cord and skeletal muscle of diseased animals treated with this compound.
URI
http://hdl.handle.net/10459.1/59522
DOI
https://doi.org/10.1007/s13311-015-0399-x
És part de
Neurotherapeutics, 2016, vol. 13, p. 198-216
Projectes de recerca europeus
Col·leccions
  • Articles publicats (IRBLleida) [1164]
  • Articles publicats (Medicina Experimental) [349]
  • Publicacions de projectes de recerca del Plan Nacional [2953]

Contacteu amb nosaltres | Envia comentaris | Avís legal
© 2023 BiD. Universitat de Lleida
Metadades subjectes a 
 

 

Explora

Tot el repositoriComunitats i col·leccionsPer data d'edicióAutorsTítolsMatèriesAquesta col·leccióPer data d'edicióAutorsTítolsMatèries

Estadístiques

Veure estadístiques d'ús

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contacteu amb nosaltres | Envia comentaris | Avís legal
© 2023 BiD. Universitat de Lleida
Metadades subjectes a